At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Nov 29, 2016
In wide-ranging interview, Hava discusses advances in treating respiratory diseases using inhaled drugs, among other topics
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its Chief Scientific...
Nov 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced it third quarter financial...
Oct 11, 2016
New study shows that Pulmatrix's inhaled drug delivery platform successfully delivers higher doses of an antifungal drug to the lungs compared to oral delivery.
Pulmatrix, Inc. (NASDAQ: PULM) will present promising new preclinical data about its inhaled antifungal drug PUR1900 in a poster at the North American Cystic Fibrosis Conference. "The preclinical...
Oct 3, 2016
Dr. Sherman's extensive experience in developing drugs in oncology and other therapeutic areas will help Pulmatrix target more diseases, potentially including cancer.
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, announced today that the company has appointed Matthew L. Sherman, M.D., Executive Vice President and...
Sep 23, 2016
Recent white paper by Envigo explains the advantages of delivering drugs to the lungs--and describes how this delivery method is increasingly being used for a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM) today announced that a recent white paper, What is the future of inhalation delivery?, by global research and consulting firm Envigo predicts rapid growth for drugs...